

## Servier U.S. – A Leader in Oncology

*Delivering transformative precision therapies to patients living with cancer*

Servier is a privately held pharmaceutical company, launched in the U.S. by Servier Group in 2018. Governed by a non-profit foundation, Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities. We are the leader in IDH-mutant targeted therapies and devote more than 65% of our research and development budget to Oncology. We aspire to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. At Servier, we believe we can serve more people by helping the right patients find the right treatment, at the right time.

### **Building the Future of Precision Therapies through Innovation, Strategic Partnerships and Acquisitions**

Servier was the first company to deliver an IDH inhibitor to patients living with IDH-mutant cancers. Our commitment to therapeutic progress guides our collaboration strategy. While many companies across the industry are scaling back investments, Servier is actively building alliances, completing acquisitions, conducting licensing deals and entering new partnerships that can help to accelerate access to therapies for patients in need. With our commercial and scientific expertise, global reach and commitment to clinical excellence, we are dedicated to bringing the promise of tomorrow to the patients we serve.

Servier's acquisition of Shire's oncology business in 2018 included ASPARLAS® (calaspargase pegol-mknl) for acute lymphoblastic leukemia, and helped us establish an immediate and direct commercial presence in the U.S. Our 2021 acquisition of Agios Pharmaceuticals' oncology portfolio, set the stage for the approvals of TIBSOVO® (ivosidenib tablets) in acute myeloid leukemia, cholangiocarcinoma and myelodysplastic syndromes, and VORANIGO® (vorasidenib), the first and only FDA-approved targeted treatment in Grade 2 IDH-mutant glioma<sup>1</sup> and the first major breakthrough in this specific disease area in nearly 25 years. VORANIGO® is the sixth approval for Servier in IDH-mutant cancers, showcasing our steadfast commitment to pipeline development in new and underserved disease areas. In just five years, Servier has more than doubled its portfolio, establishing itself as a pioneer in targeted mutant IDH inhibition and emphasizing the critical role of mutational testing to help guide treatment decisions and potentially improve patient outcomes.

### **Value-Based Factors Inform our Pricing**

The value patients get from our medicines inspires us every day to ensure those medicines continue to be accessible. We incorporate patient perspectives into everything we do including pricing, considering the financial burdens and impacts on a patient's survival, adherence to treatment and quality of life. When setting a list price for a medicine we also factor in the cost of research and development, manufacturing, U.S. government regulations, health plans and insurers, and economic factors including inflation rates, all with the goal of striking a balance between affordability and innovation to ensure patients can access our medicines and we can continue to develop them. We work closely with commercial and government payers to ensure patients have access to our therapies and we have a best-in-class patient access program, ServierONE, to support patients and caregivers every step of the way. A key element of this approach is our commitment to ensuring our patients in the U.S. have access to our treatments, regardless of their financial or social circumstances.

#### References

\*Servier, (2024, May 14). Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey [Press Release] <https://servier.us/blog/servier-ranks-1st-across-several-categories-patientview-survey/>

1. Servier. (2024, August 6). Servier's VORANIGO (vorasidenib) tablets receive FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma . Retrieved from Servier.us: <https://servier.us/blog/serviers-voranigo-vorasidenib-tablets-receives-fda-approval-as-first-targeted-therapy-for-grade-2-idh-mutant-glioma/>

**Serving Patients is our No.1 Priority**

- Ranked 1st for patient centricity, information sharing, integrity, services 'beyond the pill', engagement and communication and overall familiarity in the industry in 2023-2024 PatientView U.S. Corporate Reputation Survey\*
- Recipient of the Patient Champion Award at Reuter's Annual Pharma Awards USA
- More than 30,000 patients served